Candriam Luxembourg S.C.A. continued to hold its stake in shares of Agenus Inc. (NASDAQ:AGEN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 547,700 shares of the biotechnology company’s stock at the end of the second quarter. Candriam Luxembourg S.C.A.’s holdings in Agenus were worth $2,142,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. AQR Capital Management LLC purchased a new position in Agenus during the fourth quarter valued at $143,000. SG Americas Securities LLC boosted its position in Agenus by 175.7% in the first quarter. SG Americas Securities LLC now owns 37,171 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 23,689 shares during the last quarter. American International Group Inc. boosted its position in Agenus by 7.1% in the first quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 2,984 shares during the last quarter. Quotient Investors LLC boosted its position in Agenus by 8.8% in the first quarter. Quotient Investors LLC now owns 47,000 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 3,800 shares during the last quarter. Finally, UBS Asset Management Americas Inc. boosted its position in Agenus by 203.7% in the first quarter. UBS Asset Management Americas Inc. now owns 51,933 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 34,833 shares during the last quarter. 42.78% of the stock is owned by institutional investors and hedge funds.

Agenus Inc. (NASDAQ AGEN) opened at 3.48 on Friday. The firm’s 50-day moving average price is $4.32 and its 200 day moving average price is $3.90. The company’s market cap is $347.00 million. Agenus Inc. has a 52-week low of $3.20 and a 52-week high of $7.49.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.04. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 280.96%. The firm had revenue of $4.21 million for the quarter, compared to analysts’ expectations of $6.66 million. During the same quarter in the prior year, the firm earned ($0.33) EPS. The business’s revenue for the quarter was down 36.1% compared to the same quarter last year. On average, equities analysts predict that Agenus Inc. will post ($1.17) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Candriam Luxembourg S.C.A. Has $2,142,000 Position in Agenus Inc. (AGEN)” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/candriam-luxembourg-s-c-a-has-2142000-position-in-agenus-inc-agen/1472861.html.

Several research analysts have weighed in on AGEN shares. ValuEngine cut Agenus from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 8th. Zacks Investment Research upgraded Agenus from a “sell” rating to a “buy” rating and set a $4.50 price objective on the stock in a research report on Wednesday, July 5th. Maxim Group reiterated a “buy” rating and set a $7.00 price objective on shares of Agenus in a research report on Sunday, April 23rd. BidaskClub upgraded Agenus from a “hold” rating to a “buy” rating in a research report on Monday, July 24th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $7.00 price objective on shares of Agenus in a research report on Friday, August 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $5.88.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGEN).

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.